Modified PPR Protein Therapy for DM1 RNA Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no fundamental therapeutic drug for myotonic dystrophy type 1 (DM1), with existing treatments limited to palliative therapy.
Innovation Solution
A pharmaceutical composition comprising a nucleic acid encoding a protein with specific pentatricopeptide repeat (PPR) motifs that bind to the CUG repeat sequence, integrated into an expression or viral vector, particularly an adeno-associated virus (AAV) vector, to target and correct splicing abnormalities in DM1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palliative therapy is used for DM1, then current treatment limitations are acknowledged, but no fundamental therapeutic effect is achieved
Solution Approach 1:
The patent introduces a PPR protein as an intermediary substance that binds to CUG repeat sequences in mRNA, preventing their aggregation into RNA foci and restoring normal splicing. This mediator approach transforms the disease mechanism from passive accumulation to active correction, achieving fundamental therapeutic effects rather than mere palliation.
Solution Approach 2:
The patent replaces the mechanical/palliative approach of symptom management with a molecular-level biochemical mechanism. By designing a protein that specifically binds to and corrects the CUG repeat sequences through molecular interactions, the therapy operates at the fundamental biochemical level rather than providing only symptomatic relief.
2Reliability
If PPR protein is designed to bind CUG repeat sequences, then splicing abnormalities are corrected, but protein structure complexity increases
Solution Approach 1:
The PPR protein is segmented into multiple modular PPR motifs (typically 6-24 repeats), each motif being a standardized 30-38 amino acid sequence capable of binding specific RNA bases. This segmentation allows the protein to achieve high binding specificity through multiple identical or similar units, simplifying the design process while maintaining high affinity and specificity for CUG repeats.
Solution Approach 2:
The patent employs parameter changes in the PPR motif sequence, particularly at specific positions (A1, A4, and Lii), to tune the binding specificity toward CUG repeats. By adjusting amino acid parameters at these conserved positions, the protein achieves optimized binding characteristics without requiring complete redesign of the entire protein structure.
3Reliability
If multiple PPR motifs are used in the protein, then binding affinity to CUG repeats increases, but manufacturing complexity increases
Solution Approach 1:
The PPR motifs are designed with universal characteristics where each motif can potentially bind to different bases (A, U, G, or C) depending on the amino acid composition at key positions. This universality allows a single protein family to target multiple sequences, and in the case of DM1, multiple copies of CUG-binding motifs can be used to achieve high affinity binding to extensive CUG repeat sequences.
Solution Approach 2:
The patent utilizes parameter changes at specific amino acid positions (A1, A4, Lii) within each PPR motif to optimize binding affinity. By carefully selecting amino acid combinations at these positions, high binding affinity is achieved without requiring excessive numbers of motifs, thus balancing manufacturing complexity with therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PPR protein effectively treats or alleviates symptoms of DM1 by reducing RNA-foci formation, improving splicing abnormalities, and enhancing muscle differentiation in model cells and animals.
Implementation Method 1
a protein that specifically binds to the CUG repeat sequence
Data Source
AI summary
The object of the present invention is to provide a pharmaceutical composition or a method that is effective for treating myotonic dystrophy type 1 (DM1). Provided is a therapeutic drug or method for DM1 that utilizes a modified PPR protein.